CENTOGENE provides the full spectrum of modern methods and technology for human genetics analysis; it is active in research and is constantly developing new and innovative products for human genetics. 

We are committed to “un-rare” rare diseases by using our worldwide knowledge in the rare disease market, understanding the epidemiology, analyzing clinical heterogeneity of the more than 3800 diseases and developing innovative biomarkers. Based on this knowledge we are bringing rationality to treatment decisions and, thereby, accelerate the development of new orphan drugs.

Active in over 115 countries, we combine our genetic and medical expertise with the local market knowledge of our international partners. CENTOGENE is proud to be actively involved in supporting education on genetic testing, and the profoundly positive impact it can on patients when it allows them to receive a diagnosis, particularly at the early stages of disease onset.